Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Beyond these primary endpoints, TRIUMPH-1 includes a range of secondary and exploratory endpoints that paint a fuller picture of retatrutide's clinical impact: Proportion of participants achieving 10%, 15%, and 20% or greater weight loss Changes in waist circumference Changes in cardiometabolic risk factors, including blood pressure, triglycerides, HDL cholesterol, LDL cholesterol, and fasting glucose Changes in HbA1c (a measure of average blood sugar over the preceding two to three months) Changes in liver enzymes and markers of hepatic health Patient-reported outcomes related to quality of life and physical function Safety and tolerability, including the incidence and severity of adverse events The secondary endpoints are particularly important for retatrutide because the Phase 2 data showed striking improvements across metabolic markers
Rate constants were determined from one-phase exponential curve fitting in Prism 8.0
The compound has become one of the most extensively studied research peptides in the field of tissue repair, with multiple animal model studies examining its observed effects on wound healing, angiogenesis, and cellular migration
The frequency of these side effects varies by product and dosefor example, nausea occurs in approximately 15-20% of patients using Ozempic for diabetes management, while rates are higher with Wegovy's 2.4 mg dose for weight management
This article is not another warning designed to scare you
US$ 22.27
US$ 29.42
US$ 27.39
US$ 26.72
US$ 20.79
US$ 21.65
US$ 22.75
US$ 29.50
US$ 23.89
US$ 28.35
US$ 28.33
